Combined CRAFITY score and α-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving anti-programmed death-1 blockade-based immunotherapy
AJCR Copyright © 2023..
Biomarkers for predicting the treatment efficacy of immune checkpoint inhibitor (ICI)-based therapy in patients with unresectable hepatocellular carcinoma (uHCC) are crucial. Previous studies demonstrated that C-reactive protein and alpha-fetoprotein (AFP) in immunotherapy (CRAFITY) score at baseline predicted treatment outcomes and that patients with uHCC with AFP response, defined as > 15% decline in AFP level within the initial 3 months of ICI-based therapy, had favorable outcomes when receiving ICI-based therapy. However, whether the combination of CRAFITY score and AFP response could be used to predict treatment efficacy of programmed death-1 (PD-1) blockade-based therapy in uHCC patients remains unclear. We retrospectively enrolled 110 consecutive uHCC patients from May 2017 to March 2022. The median ICI treatment duration was 2.85 (1.67-6.63) months, and 87 patients received combination therapies. The objective response and disease control rates were 21.8% and 46.4%, respectively. The duration of progression-free survival (PFS) and overall survival (OS) was 2.87 (2.16-3.58) months and 8.20 (4.23-12.17) months, respectively. We categorized patients into three groups based on CRAFITY score (2 vs 0/1) and AFP response: patients with a CRAFITY score of 0/1 and AFP response (Group 1), those with a CRAFITY score of 2 and no AFP response (group 3), and those who did not belong to Group 1 and 3 (i.e., Group 2). The combination of CRAFITY score and AFP response could predict disease control and could predict PFS compared with CRAFITY score or AFP response alone. The combination of CRAFITY score and AFP response was an independent predictor of OS (Group 2 vs Group 1, HR: 4.513, 95% CI 1.990-10.234; Group 3 vs Group 1, HR: 3.551, 95% CI 1.544-8.168). Our findings indicated that the combination of CRAFITY score and AFP response could predict disease control, PFS, and OS in uHCC patients receiving PD-1 blockade-based immunotherapy.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
American journal of cancer research - 13(2023), 2 vom: 14., Seite 654-668 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hsu, Wei-Fan [VerfasserIn] |
|---|
| Themen: |
AFP response |
|---|
| Anmerkungen: |
Date Revised 11.03.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM354016806 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354016806 | ||
| 003 | DE-627 | ||
| 005 | 20231226061320.0 | ||
| 007 | tu | ||
| 008 | 231226s2023 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1180.xml |
| 035 | |a (DE-627)NLM354016806 | ||
| 035 | |a (NLM)36895987 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hsu, Wei-Fan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combined CRAFITY score and α-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving anti-programmed death-1 blockade-based immunotherapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 11.03.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a AJCR Copyright © 2023. | ||
| 520 | |a Biomarkers for predicting the treatment efficacy of immune checkpoint inhibitor (ICI)-based therapy in patients with unresectable hepatocellular carcinoma (uHCC) are crucial. Previous studies demonstrated that C-reactive protein and alpha-fetoprotein (AFP) in immunotherapy (CRAFITY) score at baseline predicted treatment outcomes and that patients with uHCC with AFP response, defined as > 15% decline in AFP level within the initial 3 months of ICI-based therapy, had favorable outcomes when receiving ICI-based therapy. However, whether the combination of CRAFITY score and AFP response could be used to predict treatment efficacy of programmed death-1 (PD-1) blockade-based therapy in uHCC patients remains unclear. We retrospectively enrolled 110 consecutive uHCC patients from May 2017 to March 2022. The median ICI treatment duration was 2.85 (1.67-6.63) months, and 87 patients received combination therapies. The objective response and disease control rates were 21.8% and 46.4%, respectively. The duration of progression-free survival (PFS) and overall survival (OS) was 2.87 (2.16-3.58) months and 8.20 (4.23-12.17) months, respectively. We categorized patients into three groups based on CRAFITY score (2 vs 0/1) and AFP response: patients with a CRAFITY score of 0/1 and AFP response (Group 1), those with a CRAFITY score of 2 and no AFP response (group 3), and those who did not belong to Group 1 and 3 (i.e., Group 2). The combination of CRAFITY score and AFP response could predict disease control and could predict PFS compared with CRAFITY score or AFP response alone. The combination of CRAFITY score and AFP response was an independent predictor of OS (Group 2 vs Group 1, HR: 4.513, 95% CI 1.990-10.234; Group 3 vs Group 1, HR: 3.551, 95% CI 1.544-8.168). Our findings indicated that the combination of CRAFITY score and AFP response could predict disease control, PFS, and OS in uHCC patients receiving PD-1 blockade-based immunotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AFP response | |
| 650 | 4 | |a CRAFITY score | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a programmed death-1 blockade | |
| 650 | 4 | |a survival | |
| 700 | 1 | |a Lai, Hsueh-Chou |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Cheng-Kuo |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hung-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Chuang, Po-Heng |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Ming-Hung |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Sheng-Hung |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Chia-Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Wen-Pang |e verfasserin |4 aut | |
| 700 | 1 | |a Chou, Jen-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Kao, Jung-Ta |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Hung-Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Chuang, Shih-Chieh |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Tsung-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Hsiao, Wang-De |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Guan-Tarn |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Cheng-Yuan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of cancer research |d 2011 |g 13(2023), 2 vom: 14., Seite 654-668 |w (DE-627)NLM207988722 |x 2156-6976 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:2 |g day:14 |g pages:654-668 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 2 |b 14 |h 654-668 | ||